SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System

PHASE3CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

February 28, 2011

Conditions
Coronary DiseaseCoronary Artery DiseaseCoronary Restenosis
Interventions
DEVICE

XIENCE V® Everolimus Eluting Coronary Stent

Drug eluting stent implantation stent in the treatment of coronary artery disease.

DEVICE

TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent

Drug eluting stent implantation stent in the treatment of coronary artery disease

Trial Locations (32)

1160

Wilheminenspital der Stadt Wien, Vienna

2020

A.Z. Middelheim, Antwerp

4000

C.H.R. La Citadelle, Liège

C.H.U. de Liège Sart Tilman, Liège

23795

Segeberger Kliniken GmbH, Bad Segeberg

32545

Herzzentrum Bad Oeynhausen, Bad Oeynhausen

110017

Max Devki Devi Heart & Vascular Institute, New Delhi

Unknown

Aalborg Sygehus Syd, Aalborg

Århus University Hospital, Aarhus

Rigshospitalet, Copenhagen

Hôpital Cochin, Paris

Clinique Saint Hilaire, Rouen

Clinique Pasteur, Toulouse

Hôpital de Rangueil CHU, Toulouse

Clinique Saint Gatien, Tours

Amper Kliniken AG Klinikum Dachau, Dachau

Herz- und Gefäßzentrum Hamburg, Hamburg

Klinikum Kassel, Kassel

Azienda Ospedaliera Santa Maria Nuova, Reggio Emilia

Amphia Hospital, Breda

St. Antonius Ziekenhuis Nieuwegein, Nieuwegein

Erasmus Medical Center, Rotterdam

Isala Klinieken - Locatie Weezenlanden, Zwolle

The Mercy Hospital, Auckland

Auckland City Hospital, Auckland

National Institute of Cardiology in Warsaw, Warsaw

Vergelegen Mediclinic, Cape Town

Hospital Clinico San Carlos, Madrid

University Hospital Gregorio Maranon, Madrid

Kantonsspital Basel, Basel

R.V. Hôpital Cantonal Universitaire de Geneve, Geneva

1105 AZ

Academisch Medisch Centrum, Amsterdam

Sponsors
All Listed Sponsors
lead

Abbott Medical Devices

INDUSTRY